Genomic characterization of ER-positive primary tumors and corresponding relapses identifies potentially targetable alterations

Caroline Schagerholm Stanev, Stephanie Robertson, Hosein Toosi, Emmanouil G. Sifakis, Jens Lagergren, Johan Hartman · 2026

Read Genomic characterization of ER-positive primary tumors and corresponding relapses identifies potentially targetable alterations by Caroline Schagerholm Stanev, Stephanie Robertson, Hosein Toosi, Emmanouil G. Sifakis, Jens Lagergren, Johan Hartman (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13526021.txt.

Description

Most breast cancers feed on estrogen, and hormone therapy works at first, yet about a third of patients relapse. Caroline Schagerholm Stanev and co-authors compared the genes of first tumors and their relapses in this 2026 study. The patients had estrogen-positive tumors that came back within five years of hormone therapy, still carrying the estrogen receptor. Gene changes are suspected of driving that resistance.

DNA from fifty-eight first tumors and fifty-four paired relapses was read with a targeted gene panel. RNA was measured as well, and tumor-free lymph nodes gave each patient's normal DNA for comparison. Some single-letter changes and copy changes tied, in early analysis, to worse survival. Copy patterns also lined up with tumor subtypes. Finding changes that drugs can target could open options after relapse.

Catalog record

CREATORCaroline Schagerholm Stanev, Stephanie Robertson, Hosein Toosi, Emmanouil G. Sifakis, Jens Lagergren, Johan Hartman
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE46 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13526021

Browse the full library · About the Tower of Babel